Question · asked by 1 review
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel: Quality of life ‐ not measured
- Population
- women with recurrent epithelial ovarian cancer
- Intervention
- 175 mg/m2 paclitaxel
- Comparison
- 250 mg/m2 paclitaxel
- Outcome
- Quality of life ‐ not measured
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Quality of Life ‐ not measured · women with recurrent epithelial ovarian cancer The review found no eligible studies for this question. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.